You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFenofibrate
Accession NumberDB01039  (APRD00405, DB09545)
TypeSmall Molecule
GroupsApproved
DescriptionAn antilipemic agent which reduces both cholesterol and triglycerides in the blood. [PubChem]
Structure
Thumb
Synonyms
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
Fenofibrate
Fenofibrato
Fenofibratum
Fenofibric acid
Finofibrate
FNF
Isopropyl (4'-(P-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
Procetofen
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AntaraCapsule90 mg/1OralLupin Pharma2013-11-01Not applicableUs
AntaraCapsule43 mg/1OralLupin Pharma2009-09-25Not applicableUs
AntaraCapsule130 mg/1OralLupin Pharma2009-09-25Not applicableUs
AntaraCapsule30 mg/1OralLupin Pharma2013-11-01Not applicableUs
Ava-fenofibrate MicroCapsule200 mgOralAvanstra Inc2011-08-222014-08-21Canada
Dom-fenofibrate MicroCapsule200 mgOralDominion Pharmacal1999-12-16Not applicableCanada
Dom-fenofibrate SupraTablet100 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-fenofibrate SupraTablet160 mgOralDominion PharmacalNot applicableNot applicableCanada
Feno-micro-200Capsule200 mgOralPro Doc Limitee1999-08-27Not applicableCanada
FenofibrateTablet48 mg/1OralTeva Pharmaceuticals USA Inc2016-02-09Not applicableUs
FenofibrateTablet48 mg/1OralZydus Pharmaceuticals USA Inc2004-11-05Not applicableUs
FenofibrateTablet145 mg/301OralNorthwind Pharmaceuticals2014-05-20Not applicableUs
FenofibrateTablet48 mg/1OralA S Medication Solutions2004-11-05Not applicableUs
FenofibrateCapsule150 mg/1OralANI Pharmaceuticals, Inc.2016-04-13Not applicableUs
FenofibrateTablet145 mg/1OralCarilion Materials Management2004-11-05Not applicableUs
FenofibrateTablet40 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2015-06-24Not applicableUs
FenofibrateTablet120 mg/1OralOceanside Pharmaceuticals2010-11-182016-02-25Us
FenofibrateTablet145 mg/1OralTeva Pharmaceuticals USA Inc2016-02-09Not applicableUs
FenofibrateTablet145 mg/1OralNorthwind Pharmaceuticals2015-04-28Not applicableUs
FenofibrateCapsule43 mg/1OralLupin Pharmaceuticals, Inc.2013-02-22Not applicableUs
FenofibrateTablet145 mg/1OralZydus Pharmaceuticals USA Inc2004-11-05Not applicableUs
FenofibrateTablet48 mg/1OralCarilion Materials Management2004-11-05Not applicableUs
FenofibrateCapsule50 mg/1OralH2 Pharma, Llc2014-05-05Not applicableUs
FenofibrateTablet120 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2015-06-24Not applicableUs
FenofibrateTablet48 mg/1OralZydus Pharmaceuticals USA Inc2016-02-09Not applicableUs
FenofibrateTablet145 mg/1OralTeva Pharmaceuticals USA Inc2004-11-05Not applicableUs
FenofibrateCapsule130 mg/1OralLupin Pharmaceuticals, Inc.2013-02-22Not applicableUs
FenofibrateCapsule150 mg/1OralH2 Pharma, Llc2014-05-05Not applicableUs
FenofibrateCapsule50 mg/1OralANI Pharmaceuticals, Inc.2016-04-13Not applicableUs
FenofibrateTablet145 mg/1OralZydus Pharmaceuticals USA Inc2016-02-09Not applicableUs
FenofibrateTablet48 mg/1OralTeva Pharmaceuticals USA Inc2004-11-05Not applicableUs
FenofibrateTablet40 mg/1OralOceanside Pharmaceuticals2010-11-182016-02-25Us
FenofibrateTablet145 mg/1OralUnit Dose Services2004-11-05Not applicableUs
Fenofibrate MicroCapsule200 mgOralSanis Health Inc2010-02-25Not applicableCanada
Fenofibrate-STablet100 mgOralSanis Health Inc2010-11-23Not applicableCanada
Fenofibrate-STablet160 mgOralSanis Health Inc2010-11-23Not applicableCanada
Fenofibric AcidCapsule, delayed release45 mg/1OralZydus Pharmaceuticals USA Inc2016-09-12Not applicableUs
Fenofibric AcidCapsule, delayed release45 mg/1OralImpax Generics2008-12-15Not applicableUs
Fenofibric AcidCapsule, delayed release45 mg/1OralImpax Generics2016-09-12Not applicableUs
Fenofibric AcidTablet35 mg/1OralMutual Pharmaceutical Company, Inc.2009-08-31Not applicableUs
Fenofibric AcidCapsule, delayed release135 mg/1OralZydus Pharmaceuticals USA Inc2016-09-12Not applicableUs
Fenofibric AcidCapsule, delayed release135 mg/1OralImpax Generics2008-12-15Not applicableUs
Fenofibric AcidCapsule, delayed release135 mg/1OralImpax Generics2016-09-12Not applicableUs
Fenofibric AcidTablet105 mg/1OralMutual Pharmaceutical Company, Inc.2009-08-31Not applicableUs
Fenofibric AcidTablet35 mg/1OralHalton Laboratories2015-07-30Not applicableUs
Fenofibric AcidCapsule, delayed release45 mg/1OralZydus Pharmaceuticals USA Inc2008-12-15Not applicableUs
Fenofibric AcidTablet105 mg/1OralHalton Laboratories2015-07-30Not applicableUs
Fenofibric AcidCapsule, delayed release135 mg/1OralZydus Pharmaceuticals USA Inc2008-12-15Not applicableUs
FenoglideTablet120 mg/1OralSantarus, Inc.2010-11-18Not applicableUs
FenoglideTablet120 mg/1OralPhysicians Total Care, Inc.2010-04-28Not applicableUs
FenoglideTablet40 mg/1OralShore Therapeutics, Inc2010-11-18Not applicableUs
FenoglideTablet120 mg/1OralShore Therapeutics, Inc2010-11-18Not applicableUs
FenoglideTablet40 mg/1OralSantarus, Inc.2010-11-18Not applicableUs
FenomaxCapsule100 mgOralCipher Pharmaceuticals IncNot applicableNot applicableCanada
FenomaxCapsule160 mgOralCipher Pharmaceuticals Inc2006-11-14Not applicableCanada
FibricorTablet105 mg/1OralAR Scientific, Inc.2009-08-14Not applicableUs
FibricorTablet35 mg/1OralCaraco Pharma, Inc.2009-08-14Not applicableUs
FibricorTablet105 mg/1OralTribute Pharmaceuticals Us, Inc.2015-07-30Not applicableUs
FibricorTablet105 mg/1OralCaraco Pharma, Inc.2009-08-14Not applicableUs
FibricorTablet35 mg/1OralAR Scientific, Inc.2009-08-14Not applicableUs
FibricorTablet35 mg/1OralTribute Pharmaceuticals Us, Inc.2015-07-30Not applicableUs
Lipidil Cap 100mgCapsule100 mgOralLaboratoires Fournier S.A.S.1990-12-311997-08-11Canada
Lipidil EzTablet48 mgOralBgp Pharma Ulc2005-07-26Not applicableCanada
Lipidil EzTablet145 mgOralBgp Pharma Ulc2005-07-26Not applicableCanada
Lipidil MicroCapsule200 mgOralBgp Pharma Ulc1995-12-312016-11-09Canada
Lipidil Micro - Cap 67mgCapsule67 mgOralLaboratoires Fournier S.A.S.1999-05-272003-07-21Canada
Lipidil SupraTablet160 mgOralBgp Pharma Ulc2000-03-16Not applicableCanada
Lipidil Supra 100 mgTablet100 mgOralLaboratoires Fournier S.A.S.2000-03-162014-01-29Canada
LipofenCapsule50 mg/1OralKowa Pharmaceuticals America Inc.2007-10-01Not applicableUs
LipofenCapsule150 mg/1OralKowa Pharmaceuticals America Inc.2007-10-01Not applicableUs
Mylan-fenofibrate MicroCapsule200 mgOralMylan Pharmaceuticals Ulc1999-05-26Not applicableCanada
Novo-fenofibrateCapsule100 mgOralNovopharm Limited1998-01-232005-08-10Canada
Novo-fenofibrate MicronizedCapsule200 mgOralNovopharm Limited2001-04-202015-10-26Canada
Novo-fenofibrate MicronizedCapsule67 mgOralNovopharm Limited2001-04-202015-10-26Canada
Ntp-fenofibrate-STablet100 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-fenofibrate-STablet160 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-feno-microCapsule200 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-feno-microCapsule67 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-fenofibrateCapsule100 mgOralNu Pharm Inc1996-08-292012-09-04Canada
PHL-fenofibrate MicroCapsule200 mgOralPharmel Inc2003-04-232016-10-25Canada
PHL-fenofibrate SupraTablet160 mgOralPharmel IncNot applicableNot applicableCanada
PHL-fenofibrate SupraTablet100 mgOralPharmel IncNot applicableNot applicableCanada
PMS-fenofibrateCapsule100 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-fenofibrate MicroCapsule200 mgOralPharmascience Inc1999-04-192016-10-28Canada
PMS-fenofibrate MicroCapsule200 mgOralPharmascience Inc2005-11-29Not applicableCanada
PMS-fenofibrate SupraTablet100 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-fenofibrate SupraTablet160 mgOralPharmascience IncNot applicableNot applicableCanada
Pro-feno-super - 100Tablet100 mgOralPro Doc Limitee2008-07-10Not applicableCanada
Pro-feno-super - 160Tablet160 mgOralPro Doc Limitee2008-07-10Not applicableCanada
Q-fenofibrate MicroCapsule200 mgOralQd Pharmaceuticals Ulc2012-05-292015-08-21Canada
Ran-fenofibrate ETablet145 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-fenofibrate STablet100 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-fenofibrate STablet160 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ratio-fenofibrate McCapsule200 mgOralTeva Canada Limited2004-04-05Not applicableCanada
Riva-fenofibrate MicroCapsule200 mgOralLaboratoire Riva Inc2003-03-122016-05-31Canada
Sandoz Fenofibrate ETablet48.0 mgOralSandoz Canada Incorporated2012-12-12Not applicableCanada
Sandoz Fenofibrate ETablet145.0 mgOralSandoz Canada Incorporated2012-08-24Not applicableCanada
Sandoz Fenofibrate STablet160 mgOralSandoz Canada Incorporated2007-01-11Not applicableCanada
Sandoz Fenofibrate STablet200 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Fenofibrate STablet100 mgOralSandoz Canada Incorporated2007-01-11Not applicableCanada
Teva-fenofibrate-STablet100 mgOralTeva Canada Limited2007-02-20Not applicableCanada
Teva-fenofibrate-STablet160 mgOralTeva Canada Limited2007-02-20Not applicableCanada
TricorTablet48 mg/1OralPhysicians Total Care, Inc.2005-02-16Not applicableUs
TricorTablet48 mg/1OralAbb Vie Inc.2004-11-05Not applicableUs
TricorTablet145 mg/1OralA S Medication Solutions2004-11-05Not applicableUs
TricorTablet145 mg/1OralAbb Vie Inc.2004-11-05Not applicableUs
TricorTablet48 mg/1OralAbb Vie Inc.2016-02-05Not applicableUs
TricorTablet48 mg/1OralCardinal Health2004-11-05Not applicableUs
TricorTablet145 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-20Not applicableUs
TricorTablet145 mg/1OralA S Medication Solutions2004-11-05Not applicableUs
TricorTablet145 mg/1OralPhysicians Total Care, Inc.2004-12-29Not applicableUs
TricorTablet145 mg/1OralAbb Vie Inc.2016-02-05Not applicableUs
TricorTablet145 mg/1OralAphena Pharma Solutions Tennessee, Llc2004-11-05Not applicableUs
TricorTablet145 mg/1OralCardinal Health2004-11-05Not applicableUs
TriglideTablet160 mg/1OralShionogi Inc.2005-05-07Not applicableUs
TrilipixCapsule, delayed release135 mg/1OralPhysicians Total Care, Inc.2009-02-19Not applicableUs
TrilipixCapsule, delayed release135 mg/1OralAbb Vie Inc.2008-12-15Not applicableUs
TrilipixCapsule, delayed release45 mg/1OralAbb Vie Inc.2016-09-12Not applicableUs
TrilipixCapsule, delayed release45 mg/1OralAbb Vie Inc.2008-12-15Not applicableUs
TrilipixCapsule, delayed release135 mg/1OralAbb Vie Inc.2016-09-12Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-feno-microCapsule200 mgOralApotex Inc1999-03-29Not applicableCanada
Apo-feno-micro CapsulesCapsule67 mgOralApotex Inc2001-02-21Not applicableCanada
Apo-feno-superTablet200 mgOralApotex IncNot applicableNot applicableCanada
Apo-feno-superTablet100 mgOralApotex Inc2006-04-21Not applicableCanada
Apo-feno-superTablet160 mgOralApotex Inc2006-04-21Not applicableCanada
Apo-fenofibrateCapsule100 mgOralApotex Inc1996-10-02Not applicableCanada
FenofibrateTablet, film coated160 mg/1OralRanbaxy Pharmaceuticals Inc.2006-05-10Not applicableUs
FenofibrateTablet, film coated145 mg/1OralCamber Pharmaceuticals, Inc.2016-07-14Not applicableUs
FenofibrateTablet160 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateTablet, film coated160 mg/1OralMylan Pharmaceuticals Inc.2009-12-22Not applicableUs
FenofibrateTablet160 mg/1OralAv Kare, Inc.2015-01-07Not applicableUs
FenofibrateCapsule43 mg/1OralDr. Reddy's Laboratories Limited2014-04-07Not applicableUs
FenofibrateTablet, film coated145 mg/1OralMylan Institutional Inc.2013-06-10Not applicableUs
FenofibrateTablet, film coated160 mg/1OralSt Marys Medical Park Pharmacy2010-02-01Not applicableUs
FenofibrateCapsule134 mg/1OralAmerican Health Packaging2014-10-01Not applicableUs
FenofibrateCapsule67 mg/1OralImpax Generics2010-02-01Not applicableUs
FenofibrateTablet48 mg/1OralLupin Pharmaceuticals, Inc.2012-07-13Not applicableUs
FenofibrateTablet145 mg/1OralLUPIN LIMITED2012-07-13Not applicableUs
FenofibrateTablet160 mg/1OralKAISER FOUNDATION HOSPITALS2011-04-26Not applicableUs
FenofibrateTablet, film coated160 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-01-13Not applicableUs
FenofibrateCapsule200 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-02-01Not applicableUs
FenofibrateCapsule134 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateTablet48 mg/1OralAmerican Health Packaging2013-01-31Not applicableUs
FenofibrateTablet48 mg/1OralPerrigo New York Inc2014-08-13Not applicableUs
FenofibrateTablet48 mg/1OralAv Pak2016-09-19Not applicableUs
FenofibrateTablet40 mg/1OralMylan Pharmaceuticals Inc.2016-06-23Not applicableUs
FenofibrateTablet, coated145 mg/1OralAurobindo Pharma Limited2016-05-05Not applicableUs
FenofibrateCapsule43 mg/1OralMylan Pharmaceuticals Inc.2013-02-22Not applicableUs
FenofibrateTablet, coated54 mg/1OralKaralex Pharma LLC2009-11-20Not applicableUs
FenofibrateTablet160 mg/1OralPhysicians Total Care, Inc.2006-08-23Not applicableUs
FenofibrateCapsule43 mg/1OralRanbaxy Pharmaceuticals Inc.2015-03-02Not applicableUs
FenofibrateCapsule134 mg/1OralREMEDYREPACK INC.2011-04-13Not applicableUs
FenofibrateCapsule130 mg/1OralDr. Reddy's Laboratories Limited2014-04-07Not applicableUs
FenofibrateTablet, film coated160 mg/1Oralbryant ranch prepack2006-05-10Not applicableUs
FenofibrateTablet, film coated160 mg/1OralAphena Pharma Solutions Tennessee, Llc2006-05-10Not applicableUs
FenofibrateTablet, film coated160 mg/1OralProficient Rx LP2006-05-10Not applicableUs
FenofibrateCapsule67 mg/1OralMylan Pharmaceuticals Inc.2012-10-23Not applicableUs
FenofibrateTablet54 mg/1OralKAISER FOUNDATION HOSPITALS2011-08-03Not applicableUs
FenofibrateCapsule134 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-02-01Not applicableUs
FenofibrateTablet160 mg/301OralNorthwind Pharmaceuticals2014-05-07Not applicableUs
FenofibrateCapsule134 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
FenofibrateCapsule134 mg/1OralImpax Generics2010-02-01Not applicableUs
FenofibrateTablet145 mg/1OralLupin Pharmaceuticals, Inc.2012-07-13Not applicableUs
FenofibrateTablet, film coated54 mg/1OralProficient Rx LP2006-05-10Not applicableUs
FenofibrateTablet145 mg/1OralAv Pak2016-09-19Not applicableUs
FenofibrateTablet160 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateCapsule43 mg/1OralApotex Corp.2013-07-26Not applicableUs
FenofibrateTablet145 mg/1OralAmerican Health Packaging2013-01-31Not applicableUs
FenofibrateCapsule130 mg/1OralAv Kare, Inc.2015-12-14Not applicableUs
FenofibrateTablet120 mg/1OralMylan Pharmaceuticals Inc.2016-06-23Not applicableUs
FenofibrateCapsule67 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateCapsule130 mg/1OralMylan Pharmaceuticals Inc.2013-02-22Not applicableUs
FenofibrateTablet, coated160 mg/1OralKaralex Pharma LLC2009-11-20Not applicableUs
FenofibrateTablet54 mg/1OralPhysicians Total Care, Inc.2006-11-15Not applicableUs
FenofibrateCapsule130 mg/1OralRanbaxy Pharmaceuticals Inc.2015-03-02Not applicableUs
FenofibrateCapsule67 mg/1OralREMEDYREPACK INC.2016-01-12Not applicableUs
FenofibrateCapsule134 mg/1OralMylan Pharmaceuticals Inc.2012-10-23Not applicableUs
FenofibrateTablet54 mg/1OralAv Pak2015-08-13Not applicableUs
FenofibrateTablet160 mg/1OralAmerican Health Packaging2014-10-20Not applicableUs
FenofibrateTablet160 mg/1OralA S Medication Solutions2010-02-01Not applicableUs
FenofibrateTablet160 mg/1OralPreferred Pharmaceuticals Inc.2016-10-17Not applicableUs
FenofibrateTablet, film coated48 mg/1OralMylan Pharmaceuticals Inc.2013-05-21Not applicableUs
FenofibrateTablet160 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-02-01Not applicableUs
FenofibrateTablet, film coated160 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-24Not applicableUs
FenofibrateTablet, film coated160 mg/1OralREMEDYREPACK INC.2015-05-20Not applicableUs
FenofibrateCapsule200 mg/1OralImpax Generics2010-02-01Not applicableUs
FenofibrateTablet54 mg/1OralLupin Pharmaceuticals, Inc.2015-11-11Not applicableUs
FenofibrateTablet160 mg/1OralProficient Rx LP2015-11-23Not applicableUs
FenofibrateTablet160 mg/1OralA S Medication Solutions2010-02-01Not applicableUs
FenofibrateCapsule67 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateCapsule130 mg/1OralApotex Corp.2013-07-26Not applicableUs
FenofibrateTablet54 mg/1OralImpax Generics2010-02-01Not applicableUs
FenofibrateTablet, film coated48 mg/1OralCamber Pharmaceuticals, Inc.2016-07-14Not applicableUs
FenofibrateCapsule134 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateTablet, film coated54 mg/1OralMylan Pharmaceuticals Inc.2009-12-22Not applicableUs
FenofibrateTablet54 mg/1OralAv Kare, Inc.2015-03-31Not applicableUs
FenofibrateCapsule134 mg/1OralPhysicians Total Care, Inc.2009-02-25Not applicableUs
FenofibrateTablet, film coated54 mg/1OralRanbaxy Pharmaceuticals Inc.2006-05-10Not applicableUs
FenofibrateCapsule200 mg/1OralMylan Pharmaceuticals Inc.2012-10-23Not applicableUs
FenofibrateTablet160 mg/1OralAv Pak2015-08-13Not applicableUs
FenofibrateCapsule200 mg/1OralAmerican Health Packaging2014-10-01Not applicableUs
FenofibrateTablet145 mg/1OralPerrigo New York Inc2014-09-23Not applicableUs
FenofibrateTablet, film coated48 mg/1OralA S Medication Solutions2013-05-21Not applicableUs
FenofibrateTablet, film coated145 mg/1OralMylan Pharmaceuticals Inc.2013-05-21Not applicableUs
FenofibrateCapsule67 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-02-01Not applicableUs
FenofibrateCapsule200 mg/1OralPhysicians Total Care, Inc.2006-06-01Not applicableUs
FenofibrateTablet, film coated160 mg/1OralDIRECT RX2015-01-01Not applicableUs
FenofibrateTablet145 mg/1OralOceanside Pharmaceuticals2012-06-252015-10-31Us
FenofibrateTablet160 mg/1OralREMEDYREPACK INC.2016-04-08Not applicableUs
FenofibrateTablet160 mg/1OralLupin Pharmaceuticals, Inc.2015-11-11Not applicableUs
FenofibrateTablet, coated48 mg/1OralAurobindo Pharma Limited2016-05-05Not applicableUs
FenofibrateTablet160 mg/1OralClinical Solutions Wholesale2010-02-01Not applicableUs
FenofibrateTablet48 mg/1OralLUPIN LIMITED2012-07-13Not applicableUs
FenofibrateTablet54 mg/1OralAidarex Pharmaceuticals LLC2010-02-01Not applicableUs
FenofibrateTablet, film coated48 mg/1OralMylan Institutional Inc.2013-06-10Not applicableUs
FenofibrateCapsule67 mg/1OralSt Marys Medical Park Pharmacy2013-05-02Not applicableUs
FenofibrateTablet54 mg/1OralAmerican Health Packaging2014-10-20Not applicableUs
FenofibrateTablet160 mg/1OralImpax Generics2010-02-01Not applicableUs
Fenofibric AcidCapsule, delayed release135 mg/1OralActavis Pharma, Inc.2016-01-15Not applicableUs
Fenofibric AcidCapsule, delayed release pellets45 mg/1OralMylan Institutional Inc.2013-11-212016-11-16Us
Fenofibric AcidCapsule, delayed release pellets45 mg/1OralMylan Pharmaceuticals Inc.2013-07-15Not applicableUs
Fenofibric AcidCapsule, delayed release45 mg/1OralLupin Pharmaceuticals, Inc.2013-12-17Not applicableUs
Fenofibric AcidCapsule, delayed release pellets135 mg/1OralMylan Institutional Inc.2013-11-212016-11-16Us
Fenofibric AcidCapsule, delayed release pellets135 mg/1OralMylan Pharmaceuticals Inc.2013-07-15Not applicableUs
Fenofibric AcidCapsule, delayed release135 mg/1OralLupin Pharmaceuticals, Inc.2013-12-17Not applicableUs
Fenofibric AcidCapsule, delayed release45 mg/1OralActavis Pharma, Inc.2016-01-15Not applicableUs
Fenofibric Acid Delayed-releaseCapsule, delayed release135 mg/1OralGolden State Medical Supply, Inc.2015-09-04Not applicableUs
Fenofibric Acid Delayed-releaseCapsule, delayed release45 mg/1OralPar Pharmaceutical, Inc.2013-07-18Not applicableUs
Fenofibric Acid Delayed-releaseCapsule, delayed release135 mg/1OralPar Pharmaceutical, Inc.2013-07-18Not applicableUs
Fenofibric Acid Delayed-releaseCapsule, delayed release135 mg/1OralAmerican Health Packaging2015-02-152016-10-13Us
LofibraCapsule200 mg/1OralTeva Select Brands2002-09-03Not applicableUs
LofibraTablet, film coated54 mg/1OralTeva Select Brands2005-11-23Not applicableUs
LofibraCapsule67 mg/1OralTeva Select Brands2002-10-11Not applicableUs
LofibraTablet, film coated160 mg/1OralTeva Select Brands2005-11-23Not applicableUs
LofibraCapsule134 mg/1OralTeva Select Brands2002-09-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FenogalSMB Laboratories
LipanthylAbbott
LipantilNot Available
Lipidillbirn
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Choline fenofibrate
856676-23-8
Thumb
  • InChI Key: JWAZHODZSADEHB-UHFFFAOYSA-M
  • Monoisotopic Mass: 421.1656007
  • Average Mass: 421.92
DBSALT001885
Categories
UNIIU202363UOS
CAS number49562-28-9
WeightAverage: 360.831
Monoisotopic: 360.112836867
Chemical FormulaC20H21ClO4
InChI KeyYMTINGFKWWXKFG-UHFFFAOYSA-N
InChI
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
IUPAC Name
propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
SMILES
CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
Pharmacology
IndicationFor use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
Structured Indications
PharmacodynamicsFenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.
Mechanism of actionFenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.
TargetKindPharmacological actionActionsOrganismUniProt ID
Peroxisome proliferator-activated receptor alphaProteinyes
agonist
HumanQ07869 details
Matrix metalloproteinase-25Proteinunknown
inhibitor
HumanO43923 details
Related Articles
AbsorptionFenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide
Volume of distribution
  • 95 L [moderate renal impairment (creatinine clearance of 50 to 90 mL/min)]
  • 30 L [healthy adults]
Protein binding~99% (Serum protein binding)
MetabolismNot Available
Route of eliminationFenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.
Half life20 hours
Clearance
  • 1.2 L/h [Eldery]
ToxicityLD50=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcenocoumarolFenofibrate may increase the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideFenofibrate may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Fenofibrate.Approved
AmiodaroneThe metabolism of Fenofibrate can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Fenofibrate.Approved
AprepitantThe serum concentration of Fenofibrate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Fenofibrate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Fenofibrate can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Atorvastatin.Approved
BexaroteneThe serum concentration of Fenofibrate can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Fenofibrate can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Fenofibrate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fenofibrate can be decreased when it is combined with Bosentan.Approved, Investigational
CarbamazepineThe metabolism of Fenofibrate can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Fenofibrate can be increased when it is combined with Ceritinib.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Cerivastatin.Withdrawn
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Fenofibrate.Approved
ChlorpropamideFenofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Fenofibrate.Approved
ClarithromycinThe metabolism of Fenofibrate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Fenofibrate can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Fenofibrate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Fenofibrate can be decreased when combined with Cobicistat.Approved
Coenzyme Q10The risk or severity of adverse effects can be increased when Fenofibrate is combined with Coenzyme Q10.Experimental
ColchicineFenofibrate may increase the myopathic rhabdomyolysis activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Fenofibrate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Fenofibrate can be decreased when combined with Crizotinib.Approved
CyclosporineCyclosporine may increase the nephrotoxic activities of Fenofibrate.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Fenofibrate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Fenofibrate can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Fenofibrate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Fenofibrate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Fenofibrate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fenofibrate can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Fenofibrate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DicoumarolFenofibrate may increase the anticoagulant activities of Dicoumarol.Approved
DihydroergotamineThe metabolism of Fenofibrate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Fenofibrate can be decreased when combined with Diltiazem.Approved
DoxycyclineThe metabolism of Fenofibrate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Fenofibrate can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Fenofibrate can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Fenofibrate can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Fenofibrate can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Fenofibrate can be decreased when it is combined with Eslicarbazepine acetate.Approved
Ethyl biscoumacetateFenofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtravirineThe serum concentration of Fenofibrate can be decreased when it is combined with Etravirine.Approved
EzetimibeThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Ezetimibe.Approved
FluconazoleThe metabolism of Fenofibrate can be decreased when combined with Fluconazole.Approved
FluindioneFenofibrate may increase the anticoagulant activities of Fluindione.Investigational
FluvastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Fenofibrate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fenofibrate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fenofibrate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fenofibrate can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Fenofibrate can be increased when it is combined with Fusidic Acid.Approved
GlibornurideFenofibrate may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideFenofibrate may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideFenofibrate may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFenofibrate may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneFenofibrate may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideFenofibrate may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideFenofibrate may increase the hypoglycemic activities of Glyburide.Approved
IdelalisibThe serum concentration of Fenofibrate can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Fenofibrate can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Fenofibrate can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Fenofibrate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Fenofibrate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Fenofibrate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fenofibrate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Fenofibrate can be decreased when combined with Ketoconazole.Approved, Investigational
LopinavirThe metabolism of Fenofibrate can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Fenofibrate can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Fenofibrate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Fenofibrate can be increased when combined with Lumacaftor.Approved
MevastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Mevastatin.Experimental
MifepristoneThe serum concentration of Fenofibrate can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Fenofibrate can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Fenofibrate can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Fenofibrate can be decreased when it is combined with Nafcillin.Approved
NefazodoneThe metabolism of Fenofibrate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fenofibrate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Fenofibrate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fenofibrate can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Fenofibrate can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Fenofibrate can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Fenofibrate can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Fenofibrate can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Fenofibrate can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenindioneFenofibrate may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Fenofibrate can be increased when combined with Phenobarbital.Approved
PhenprocoumonFenofibrate may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe metabolism of Fenofibrate can be increased when combined with Phenytoin.Approved, Vet Approved
PitavastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Pitavastatin.Approved
PosaconazoleThe metabolism of Fenofibrate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Pravastatin.Approved
PrimidoneThe metabolism of Fenofibrate can be increased when combined with Primidone.Approved, Vet Approved
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Fenofibrate.Approved
RanolazineThe metabolism of Fenofibrate can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Fenofibrate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fenofibrate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fenofibrate can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Fenofibrate can be decreased when combined with Ritonavir.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Rosuvastatin.Approved
SaquinavirThe metabolism of Fenofibrate can be decreased when combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Fenofibrate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fenofibrate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fenofibrate can be increased when it is combined with Simeprevir.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Simvastatin.Approved
St. John's WortThe serum concentration of Fenofibrate can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Fenofibrate can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Fenofibrate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusTacrolimus may increase the nephrotoxic activities of Fenofibrate.Approved, Investigational
TelaprevirThe metabolism of Fenofibrate can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Fenofibrate can be decreased when combined with Telithromycin.Approved
TiclopidineThe metabolism of Fenofibrate can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Fenofibrate can be decreased when it is combined with Tocilizumab.Approved
TolazamideFenofibrate may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideFenofibrate may increase the hypoglycemic activities of Tolbutamide.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibrate.Approved, Investigational
VenlafaxineThe metabolism of Fenofibrate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Fenofibrate can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Fenofibrate can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinFenofibrate may increase the anticoagulant activities of Warfarin.Approved
ZiprasidoneThe metabolism of Fenofibrate can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Increased absorption- take with meals.
References
Synthesis Reference

Jean-Francois Boyer, “Medicine based on fenofibrate, and a method of preparing it.” U.S. Patent US4800079, issued January, 1988.

US4800079
General References
  1. Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z: Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004 Apr;42(4):212-7. [PubMed:15124979 ]
  2. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61. [PubMed:16310551 ]
External Links
ATC CodesC10AB11C10BA04C10BA03C10AB05
AHFS Codes
  • 24:06.06
PDB EntriesNot Available
FDA labelDownload (283 KB)
MSDSDownload (19.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.987
Blood Brain Barrier+0.9334
Caco-2 permeable+0.648
P-glycoprotein substrateNon-substrate0.5571
P-glycoprotein inhibitor INon-inhibitor0.5995
P-glycoprotein inhibitor IINon-inhibitor0.7632
Renal organic cation transporterNon-inhibitor0.9042
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9147
CYP450 3A4 substrateSubstrate0.6735
CYP450 1A2 substrateInhibitor0.7599
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.7619
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7088
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6373
BiodegradationNot ready biodegradable0.9918
Rat acute toxicity2.2250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9887
hERG inhibition (predictor II)Non-inhibitor0.9083
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral30 mg/1
CapsuleOral90 mg/1
CapsuleOral200 mg
CapsuleOral67 mg
TabletOral100 mg
TabletOral160 mg
TabletOral200 mg
CapsuleOral100 mg
CapsuleOral130 mg/1
CapsuleOral134 mg/1
CapsuleOral150 mg/1
CapsuleOral200 mg/1
CapsuleOral43 mg/1
CapsuleOral50 mg/1
CapsuleOral67 mg/1
TabletOral120 mg/1
TabletOral145 mg/301
TabletOral160 mg/301
TabletOral160 mg/1
TabletOral40 mg/1
TabletOral54 mg/1
Tablet, coatedOral145 mg/1
Tablet, coatedOral160 mg/1
Tablet, coatedOral48 mg/1
Tablet, coatedOral54 mg/1
Tablet, film coatedOral145 mg/1
Tablet, film coatedOral160 mg/1
Tablet, film coatedOral48 mg/1
Tablet, film coatedOral54 mg/1
Capsule, delayed release pelletsOral135 mg/1
Capsule, delayed release pelletsOral45 mg/1
Capsule, delayed releaseOral135 mg/1
Capsule, delayed releaseOral45 mg/1
CapsuleOral160 mg
TabletOral105 mg/1
TabletOral35 mg/1
TabletOral48 mg
TabletOral145 mg
TabletOral145.0 mg
TabletOral48.0 mg
TabletOral145 mg/1
TabletOral48 mg/1
Prices
Unit descriptionCostUnit
Triglide 160 mg tablet6.39USD tablet
Fenoglide 120 mg tablet5.17USD tablet
Antara 130 mg capsule5.13USD capsule
Tricor 145 mg tablet4.69USD tablet
Lipofen 150 mg capsule3.55USD capsule
Lofibra 200 mg capsule3.25USD capsule
Lofibra 160 mg tablet3.11USD tablet
Fenofibrate Micronized 200 mg capsule2.77USD capsule
Fenofibrate 160 mg2.47USD tablet
Fenofibrate 160 mg tablet2.38USD tablet
Lofibra 134 mg capsule2.03USD capsule
Antara 43 mg capsule1.8USD capsule
Fenofibrate Micronized 134 mg capsule1.79USD capsule
Fenoglide 40 mg tablet1.72USD tablet
Tricor 48 mg tablet1.63USD tablet
Triglide 50 mg tablet1.49USD tablet
Lipidil Supra 160 mg Tablet1.4USD tablet
Lofibra 67 mg capsule1.26USD capsule
Lipidil Micro 200 mg Capsule1.23USD capsule
Lipidil Supra 100 mg Tablet1.22USD tablet
Apo-Feno-Micro 200 mg Capsule1.14USD capsule
Fenofibrate Micro 200 mg Capsule1.14USD capsule
Mylan-Fenofibrate Micro 200 mg Capsule1.14USD capsule
Novo-Fenofibrate Micronized 200 mg Capsule1.14USD capsule
Pms-Fenofibrate Micro 200 mg Capsule1.14USD capsule
Ratio-Fenofibrate Mc 200 mg Capsule1.14USD capsule
Fenofibrate Micronized 67 mg capsule1.0USD capsule
Lofibra 54 mg tablet0.99USD tablet
Fenofibrate 54 mg tablet0.81USD tablet
Apo-Feno-Super 160 mg Tablet0.79USD tablet
Novo-Fenofibrate-S 160 mg Tablet0.79USD tablet
Sandoz Fenofibrate S 160 mg Tablet0.79USD tablet
Apo-Feno-Super 100 mg Tablet0.68USD tablet
Novo-Fenofibrate-S 100 mg Tablet0.68USD tablet
Sandoz Fenofibrate S 100 mg Tablet0.68USD tablet
Apo-Fenofibrate 100 mg Capsule0.64USD capsule
Apo-Feno-Micro 67 mg Capsule0.45USD capsule
Novo-Fenofibrate Micronized 67 mg Capsule0.45USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2219475 No2002-07-092017-12-11Canada
CA2487054 No2008-03-182023-05-23Canada
US5145684 No1994-01-252011-01-25Us
US6074670 No1998-01-092018-01-09Us
US6277405 No1998-01-092018-01-09Us
US6375986 No2000-09-212020-09-21Us
US6589552 No1998-01-092018-01-09Us
US6652881 No1998-01-092018-01-09Us
US6696084 No2001-09-112021-09-11Us
US7037529 No1998-01-092018-01-09Us
US7041319 No1998-01-092018-01-09Us
US7101574 No2000-08-202020-08-20Us
US7259186 No2005-01-072025-01-07Us
US7276249 No2003-02-212023-02-21Us
US7320802 No2003-02-212023-02-21Us
US7569612 No2007-08-202027-08-20Us
US7658944 No2004-12-092024-12-09Us
US7741373 No2007-08-202027-08-20Us
US7741374 No2007-08-202027-08-20Us
US7863331 No2000-08-082020-08-08Us
US7915247 No2007-08-202027-08-20Us
US8026281 No2005-04-222025-04-22Us
US8124125 No2004-10-012024-10-01Us
US8481078 No2004-10-012024-10-01Us
US9173847 No2004-10-012024-10-01Us
US9314447 No2013-05-312033-05-31Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point80.5 °CPhysProp
water solubility0.25mg/ml at 25 °CNot Available
logP5.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000707 mg/mLALOGPS
logP4.86ALOGPS
logP5.28ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.13 m3·mol-1ChemAxon
Polarizability38.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Diphenylmethane
  • Phenoxyacetate
  • Acetophenone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Alkyl aryl ether
  • Aryl halide
  • Aryl chloride
  • Ketone
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fa...
Gene Name:
PPARA
Uniprot ID:
Q07869
Molecular Weight:
52224.595 Da
References
  1. Clavey V, Copin C, Mariotte MC, Bauge E, Chinetti G, Fruchart J, Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem. 1999;9(3):139-49. [PubMed:10494028 ]
  2. Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000 May 10;271(2):445-50. [PubMed:10799317 ]
  3. Casas F, Pineau T, Rochard P, Rodier A, Daury L, Dauca M, Cabello G, Wrutniak-Cabello C: New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting. FEBS Lett. 2000 Sep 29;482(1-2):71-4. [PubMed:11018525 ]
  4. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem. 2001 Jul 13;276(28):25841-7. Epub 2001 May 7. [PubMed:11342537 ]
  5. Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti JR Jr: Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism. 2001 Aug;50(8):963-71. [PubMed:11474486 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. [PubMed:10828060 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Not Available
Gene Name:
mmp20
Uniprot ID:
O43923
Molecular Weight:
20353.66 Da
References
  1. Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F: Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension. 2007 May;49(5):1084-94. Epub 2007 Mar 12. [PubMed:17353509 ]
  2. Lebrasseur NK, Duhaney TA, De Silva DS, Cui L, Ip PC, Joseph L, Sam F: Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension. 2007 Sep;50(3):489-96. Epub 2007 Jul 2. [PubMed:17606858 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 03:38